BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 32911596)

  • 1. The Bladder EpiCheck Test as a Non-Invasive Tool Based on the Identification of DNA Methylation in Bladder Cancer Cells in the Urine: A Review of Published Evidence.
    Mancini M; Righetto M; Zumerle S; Montopoli M; Zattoni F
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32911596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic predictive value of the Bladder EpiCheck test in the follow-up of patients with non-muscle-invasive bladder cancer.
    Trenti E; D'Elia C; Mian C; Schwienbacher C; Hanspeter E; Pycha A; Kafka M; Degener S; Danuser H; Roth S; Pycha A
    Cancer Cytopathol; 2019 Jul; 127(7):465-469. PubMed ID: 31154670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial.
    Witjes JA; Morote J; Cornel EB; Gakis G; van Valenberg FJP; Lozano F; Sternberg IA; Willemsen E; Hegemann ML; Paitan Y; Leibovitch I
    Eur Urol Oncol; 2018 Sep; 1(4):307-313. PubMed ID: 31100252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical evaluation of Bladder CARE, a new epigenetic test for bladder cancer detection in urine samples.
    Piatti P; Chew YC; Suwoto M; Yamada T; Jara B; Jia XY; Guo W; Ghodoussipour S; Daneshmand S; Ahmadi H; Rice J; Bhasin J; Holloway F; Tsai Y; Chihara Y; Liang G
    Clin Epigenetics; 2021 Apr; 13(1):84. PubMed ID: 33882992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.
    Roperch JP; Grandchamp B; Desgrandchamps F; Mongiat-Artus P; Ravery V; Ouzaid I; Roupret M; Phe V; Ciofu C; Tubach F; Cussenot O; Incitti R
    BMC Cancer; 2016 Sep; 16(1):704. PubMed ID: 27586786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can we use methylation markers as diagnostic and prognostic indicators for bladder cancer?
    Kim YJ; Kim WJ
    Investig Clin Urol; 2016 Jun; 57 Suppl 1(Suppl 1):S77-88. PubMed ID: 27326410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of 2 new real-time polymerase chain reaction-based urinary markers in the follow-up of patients with non-muscle-invasive bladder cancer.
    Trenti E; Pycha S; Mian C; Schwienbacher C; Hanspeter E; Kafka M; Spedicato GA; Vjaters E; Degener S; Pycha A; D'Elia C
    Cancer Cytopathol; 2020 May; 128(5):341-347. PubMed ID: 31977131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urine cell-based DNA methylation classifier for monitoring bladder cancer.
    van der Heijden AG; Mengual L; Ingelmo-Torres M; Lozano JJ; van Rijt-van de Westerlo CCM; Baixauli M; Geavlete B; Moldoveanud C; Ene C; Dinney CP; Czerniak B; Schalken JA; Kiemeney LALM; Ribal MJ; Witjes JA; Alcaraz A
    Clin Epigenetics; 2018; 10():71. PubMed ID: 29854012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer.
    D'Andrea D; Soria F; Zehetmayer S; Gust KM; Korn S; Witjes JA; Shariat SF
    BJU Int; 2019 Jun; 123(6):959-967. PubMed ID: 30653818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis of bladder cancer recurrence based on urinary levels of EOMES, HOXA9, POU4F2, TWIST1, VIM, and ZNF154 hypermethylation.
    Reinert T; Borre M; Christiansen A; Hermann GG; Ørntoft TF; Dyrskjøt L
    PLoS One; 2012; 7(10):e46297. PubMed ID: 23056278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of bladder cancer in urine sediments by a hypermethylation panel of selected tumor suppressor genes.
    Pietrusiński M; Kȩpczyński Ƚ; Jȩdrzejczyk A; Borkowska E; Traczyk-Borszyńska M; Constantinou M; Kaƚużewski B; Borowiec M
    Cancer Biomark; 2017; 18(1):47-59. PubMed ID: 27814275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. UroMark-a urinary biomarker assay for the detection of bladder cancer.
    Feber A; Dhami P; Dong L; de Winter P; Tan WS; Martínez-Fernández M; Paul DS; Hynes-Allen A; Rezaee S; Gurung P; Rodney S; Mehmood A; Villacampa F; de la Rosa F; Jameson C; Cheng KK; Zeegers MP; Bryan RT; James ND; Paramio JM; Freeman A; Beck S; Kelly JD
    Clin Epigenetics; 2017; 9():8. PubMed ID: 28163793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments.
    Chung W; Bondaruk J; Jelinek J; Lotan Y; Liang S; Czerniak B; Issa JP
    Cancer Epidemiol Biomarkers Prev; 2011 Jul; 20(7):1483-91. PubMed ID: 21586619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct DNA methylation epigenotypes in bladder cancer from different Chinese sub-populations and its implication in cancer detection using voided urine.
    Chen PC; Tsai MH; Yip SK; Jou YC; Ng CF; Chen Y; Wang X; Huang W; Tung CL; Chen GC; Huang MM; Tong JH; Song EJ; Chang DC; Hsu CD; To KF; Shen CH; Chan MW
    BMC Med Genomics; 2011 May; 4():45. PubMed ID: 21599969
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Rose M; Bringezu S; Godfrey L; Fiedler D; Gaisa NT; Koch M; Bach C; Füssel S; Herr A; Hübner D; Ellinger J; Pfister D; Knüchel R; Wirth MP; Böhme M; Dahl E
    Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32046186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methylation study of the Paris system for reporting urinary (TPS) categories.
    Pierconti F; Martini M; Cenci T; Fiorentino V; Sacco E; Bientinesi R; Pugliese D; Iacovelli R; Schinzari G; Larocca LM; Bassi PF
    J Clin Pathol; 2021 Feb; 74(2):102-105. PubMed ID: 32527754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylomics analysis identifies ZNF671 as an epigenetically repressed novel tumor suppressor and a potential non-invasive biomarker for the detection of urothelial carcinoma.
    Yeh CM; Chen PC; Hsieh HY; Jou YC; Lin CT; Tsai MH; Huang WY; Wang YT; Lin RI; Chen SS; Tung CL; Wu SF; Chang DC; Shen CH; Hsu CD; Chan MW
    Oncotarget; 2015 Oct; 6(30):29555-72. PubMed ID: 26320192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A urine-based DNA methylation assay to facilitate early detection and risk stratification of bladder cancer.
    Ruan W; Chen X; Huang M; Wang H; Chen J; Liang Z; Zhang J; Yu Y; Chen S; Xu S; Hu T; Li X; Guo Y; Jiang Z; Chen Z; Huang J; Lin T; Fan JB
    Clin Epigenetics; 2021 Apr; 13(1):91. PubMed ID: 33902700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA Methylation Urine Biomarkers Test in the Diagnosis of Upper Tract Urothelial Carcinoma: Results from a Single-Center Prospective Clinical Trial.
    Territo A; Gallioli A; Diana P; Boissier R; Fontana M; Gaya JM; Sanguedolce F; Calderón J; Piana A; Fontanet S; Algaba F; Palou J; Breda A
    J Urol; 2022 Sep; 208(3):570-579. PubMed ID: 35549312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A DNA hypermethylation profile reveals new potential biomarkers for the evaluation of prognosis in urothelial bladder cancer.
    López JI; Angulo JC; Martín A; Sánchez-Chapado M; González-Corpas A; Colás B; Ropero S
    APMIS; 2017 Sep; 125(9):787-796. PubMed ID: 28586118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.